Prevenar 20

Active immunisation for prevention of invasive disease & pneumonia caused by Strep pneumoniae in individuals ≥18 yr; invasive disease, pneumonia & acute otitis media (OM) caused by Strep pneumoniae in infant, child & adolescent 6 wk to <18 yr.

IM 0.5 mL (1 dose). Individual ≥18 yr Single dose. Unvaccinated childn 2 to <5 yr Single dose, 12 to <24 mth 2 doses w/ at least 8 wk interval between doses, 7 to <12 mth 2 doses w/ at least 4 wk interval between doses; 3rd dose by 2nd yr. Childn & infant 6 wk to 15 mth, preterm infant <37 wk gestation Primary infant series consisting 3 doses w/ 1st dose given at 2 mth (may be given as early as 6 wk) & w/ at least 4 wk interval between doses followed by 4th (booster) dose to be administered at 11-15 mth. Adolescent & childn 5 to <18 yr regardless of prior Prevenar 13 vaccination; childn 15 mth to <5 yr previously fully vaccinated w/ Prevenar 13 Single dose; administer at least 8 wk if w/ Prevenar 13 vaccination.

Hypersensitivity to pneumococcal polysaccharide conjugate vaccine or diphtheria toxoid.

Appropriate medical treatment & supervision must be ready in case of rare anaphylactic reaction following vaccination. Do not inj intravascularly. Postpone vaccination in individuals suffering from acute severe febrile illness. Individuals w/ thrombocytopenia or bleeding disorder; carefully evaluate risk of bleeding in patients w/ coagulation disorders before vaccination. Only protects against Strep pneumoniae serotypes included in vaccine & will not protect against other microorganisms that cause invasive disease, pneumonia or OM; may not protect all individuals receiving vaccine from pneumococcal invasive disease, pneumonia or OM. May reduce immune responses to Prevenar 20 in some individuals w/ altered immunocompetence. May reduce Ab response to active immunisation in individuals w/ impaired immune response due to immunosuppressive therapy, genetic defect, HIV or other causes. Contains Na <1 mmol/dose. May temporarily affect ability to drive or use machines. Pregnancy & lactation. Potential risk of apnoea in preterm infants; consider monitoring for at least 48 hr after vaccination for preterm infant ≤28 wk of gestation who remain hospitalised at time of administration. Infant <6 wk.

Decreased appetite; headache; muscle & joint pain; fatigue; vaccination-site erythema, induration/swelling, pain/tenderness. Fever. Adolescent/child/infant: Irritability; drowsiness/increased sleep, restless sleep/decreased sleep. Diarrhoea, vomiting; rash.

Administer different inj vaccines at different vaccination sites. Do not mix w/ other vaccines/medicinal products in the same syringe.

Vaccines, Antisera & Immunologicals

J07AL02 - pneumococcus, purified polysaccharides antigen conjugated ; Belongs to the class of pneumococcal bacterial vaccines.

POM